Services at the UM Medical Center

Contenido en el Idioma Espa�ol de University of Maryland Medical Center.

Hemoglobinuria paroxística nocturna

Nombres alternativos:

HPN

Prevención:

No existe una forma conocida de prevenir esta enfermedad.

Referencias:

US Food and Drug Administration. FDA Approves First-of-its-Kind Drug to Treat Rare Blood Disorder . Rockville, MD: National Press Office; March 16, 2007. Release P07-47.

Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med . 2006 Sep 21;355(12):1233-43.

Células sanguíneas

Fecha de revisión: 3/22/2007
Versión en inglés revisada por: Corey Cutler, M.D., M.P.H., F.R.C.P.C, Department of Medical Oncology, Dana-Farber Cancer Institute; Instructor in Medicine, Harvard Medical School, Boston, MA. Review provided by VeriMed Healthcare Network.
Traducción y localización realizada por: DrTango, Inc.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.